版本:
中国

BRIEF-Trovagene says Phase 1 safety study supports planned development of PCM-075 in AML

May 25 Trovagene Inc

* Phase 1 safety study supports planned development of PCM-075 in AML

* Trovagene Inc says data is supportive of phase 1/2 clinical trial in patients with aml and is now being submitted for peer review publication by study investigators Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐